Vera Therapeutics (VERA.US) announced that the atacicept treatment trial results show its potential to prevent kidney failure in patients with immunoglobulin A nephropathy, leading to a 13% surge in the company's stock price on Monday.
The company stated that the phase 2b trial showed stable kidney function in patients with chronic kidney disease after 96 weeks of long-term observation, a condition caused by the accumulation of the protein IgA in the kidneys.
The company plans to announce the primary results of the phase 3 trial in the second quarter of 2025 and later this year submit a biologics license application to the Food and Drug Administration in the usa.
